Kym Wittholz, Amy J Bongetti, Kate Fetterplace, Marissa K Caldow, Amalia Karahalios, David P De Souza, Sheik Nadeem Elahee Doomun, Olav Rooyackers, René Koopman, Gordon S Lynch, Yasmine Ali Abdelhamid, Adam M Deane
BACKGROUND: During critical illness skeletal muscle wasting occurs rapidly. Although beta-hydroxy-beta-methylbutyrate (HMB) is a potential treatment to attenuate this process, the plasma appearance and muscle concentration is uncertain. METHODS: This was an exploratory study nested within a blinded, parallel group, randomized clinical trial in which critically ill patients after trauma received enteral HMB (3 g daily) or placebo. Plasma samples were collected at 0, 60, and 180 min after study supplement administration on day 1...
March 24, 2024: JPEN. Journal of Parenteral and Enteral Nutrition